Pulmonology’s prior-authorization burden is wide. The high-volume drug classes — severe-asthma biologics, pulmonary hypertension therapies, inhaled specialty drugs — each come with their own per-payer documentation requirements. Layered on top is the DME authorization process for CPAP and BiPAP equipment, which typically runs through a separate payer system entirely.
The result is a practice that runs a high weekly authorization volume across multiple care categories, with each category requiring documentation assembled in a different shape.
The numbers in pulmonology
Pulmonology draws heavily on the universal physician burden, because dedicated pulmonology-specific PA studies are sparse relative to specialties like oncology or rheumatology. The AMA’s 2024 Prior Authorization Physician Survey — the most rigorous cross-specialty dataset available — shows:
- ~13 hours per physician per week spent on prior authorization.
- 39 authorizations per physician per week.
- 93% of physicians report PA delays patient care.
- 82% report PA can lead patients to abandon treatment.
For severe asthma specifically, payers require documented eosinophil thresholds, exacerbation rates over the prior year, and evidence of inadequate control on high-dose inhaled corticosteroids — before approving a biologic. Those thresholds are not standardized across payers.
Why pulmonology is different
- Eosinophil-gated biologics. Mepolizumab, benralizumab, and dupilumab all require blood eosinophil counts meeting payer-specific thresholds, plus documented exacerbation history and prior-therapy failure. Each payer draws the line differently.
- Per-payer documentation. The same patient’s exacerbation history and eosinophil counts have to be assembled in each payer’s required format. A submission that clears one payer may fail another for a documentation gap, not a clinical one.
- DME through a separate queue. CPAP and BiPAP authorization for OSA runs through the DME benefit, not the medical benefit — different system, different documentation requirements, different timelines. Practices managing both are running parallel PA operations.
- Pulmonary hypertension drugs. High-cost oral and infused PAH therapies (phosphodiesterase inhibitors, endothelin antagonists, prostacyclins) carry significant PA requirements, with step-therapy rules that vary sharply by payer.
- Recurring re-authorizations. Biologic maintenance therapy requires periodic re-authorization; a lapse interrupts the treatment schedule.
What it costs
The operational cost is 13 hours a week of physician and staff time across a high-volume PA load. The clinical cost concentrates in severe asthma: a patient whose exacerbation rate qualifies them for a biologic should get it quickly — each exacerbation carries its own risk, its own emergency visit, and its own downstream care. Delays that keep patients on high-dose inhaled corticosteroids or oral steroids while the biologic authorization moves create real clinical and cost consequences. At roughly $10.81 per manually processed authorization (CAQH 2023), the overhead compounds across every drug class and every DME authorization.
How to cut the wait
The severe-asthma biologic authorization packet is structured clinical data — eosinophil counts, exacerbation history, prior therapy record. It should be assembled by software, not a staff member transcribing from a chart. Artificer Health:
- Assembles the clinical packet — eosinophil counts, exacerbation frequency over the required lookback period, and the ICS failure documentation each payer needs.
- Matches it to the payer’s criteria so the first submission satisfies that specific payer’s eosinophil threshold and step-therapy requirements.
- Handles re-authorizations for ongoing biologic therapy and flags DME authorization requirements so CPAP and BiPAP documentation goes to the right system the first time.
The goal is fewer exacerbations waiting on paperwork, and less of the pulmonologist’s 13 hours spent on it.
Sources: AMA 2024 Prior Authorization Physician Survey (n=1,000); CAQH 2023 Index. Severe-asthma biologic payer criteria (eosinophil thresholds, exacerbation history, ICS failure requirements) documented in payer medical policies.